Pierre-Yves Berclaz, Chief Science and Medical Officer at Ferring Pharmaceuticals, stated: "The ADAPT-1 trial results confirm the efficacy and safety of follitropin delta across the full range of ...

The ADAPT-1 trial was a multicentre, randomised, assessor-blind study involving 300 women aged 18-40 years undergoing IVF or ICSI. 3 The trial compared the efficacy and safety of follitropin delta ...

Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta Data presented today at the ESHRE congress builds evidence for conventional-based Follicular Stimulating Hormone (FSH) dosing ...

PARIS, July 02, 2025--Follitropin delta starting dose of 15 micrograms (µg)/day has comparable efficacy and safety as a starting dose of 225 International Units (IU)/day of follitropin alfa for ...

Follitropin delta starting dose of 15 micrograms (µg)/day has comparable efficacy and safety as a starting dose of 225 International Units (IU)/day of follitropin alfa for ovarian stimulation in ...

Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta Business Wire Jul 2, 2025 ...

Ferring Pharmaceuticals officially opened doors to its state-of-the-art gene therapy manufacturing facility in Parsippany June 17.

To promote its bladder cancer treatment, Ferring Pharmaceuticals brought in a miniature horse farmer for its latest ad campaign. At the end of last year, the drugmaker decided it was time to promote ...

Pierre-Yves Berclaz, Chief Science and Medical Officer at Ferring Pharmaceuticals, stated: "The ADAPT-1 trial results confirm the efficacy and safety of follitropin delta across the full range of ...

PARSIPPANY, N.J., December 03, 2024 -- (BUSINESS WIRE)--Ferring Pharmaceuticals today announced it has advanced three studies in the ADSTILADRIN ® (nadofaragene firadenovec-vncg) clinical trial ...

Purvi Tailor, Ferring Pharmaceuticals' VP of HR, says focusing holistically on worker well-being is crucial for retaining top talent in healthcare.